Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Terminated Phase 1 Interventional

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

NCT01003678
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Clofarabine
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Results available

Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

NCT03207958
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease
Interventions
Belimumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

NCT03238326
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
17
States / cities
Dothan, Alabama • Anaheim, California • Culver City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 4 Interventional Results available

Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

NCT02228408
View directory record Official record
Conditions
Chronic Hemodialysis (ESRD)
Interventions
Hydralazine/Isorsorbide Dinitrate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 25, 2026, 10:23 AM EDT
Terminated Phase 2 Interventional Results available

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

NCT02169505
View directory record Official record
Conditions
Lymphoma
Interventions
Brentuximab Vedotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

NCT03523351
View directory record Official record
Conditions
Metastatic Solid Tumors of Metastatic Disease
Interventions
Radiation Therapy, Systemic Therapy
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 25, 2026, 10:23 AM EDT
Recruiting Not applicable Interventional

Project neuroARTEMIS

NCT06814275
View directory record Official record
Conditions
Stimulant Use, Human Immunodeficiency Virus (HIV), Depression
Interventions
ARTEMIS, Contingency management for Antiretroviral (ARV) adherence
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 59 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

NCT05215405
View directory record Official record
Conditions
Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma
Interventions
Venetoclax, Navitoclax
Drug
Lead sponsor
Kathleen Ludwig
Other
Eligibility
4 Years and older
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of Acute Myocardial Infarction Using FDY-5301

NCT03470441
View directory record Official record
Conditions
Acute Myocardial Infarction, STEMI
Interventions
FDY-5301, Placebo
Drug · Other
Lead sponsor
Faraday Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
Recruiting Phase 1 Interventional

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

NCT07052305
View directory record Official record
Conditions
Large B-cell Lymphoma
Interventions
NT-I7, CAR T-cell therapy
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
Not yet recruiting Not applicable Interventional

Osteopathic Manipulative Treatment for Children With Chronic or Recurrent Otitis Media

NCT07639775
View directory record Official record
Conditions
Otitis Media, Otitis Media Effusion, Otitis Media Recurrent, Otitis Media With Effusion in Children, Otitis Media Chronic, Otitis Media in Children, Tympanostomy Tube Insertion, Osteopathic Manipulative Treatment (OMT)
Interventions
Experimental Osteopathic Manipulative Treatment (OMT) Protocol, Control Osteopathic Manipulative Treatment (OMT) Protocol
Other
Lead sponsor
Sarah Vidal
Other
Eligibility
6 Months to 6 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT03164057
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, ITMHA, Idarubicin, Fludarabine, Mitoxantrone, Erwinia asparaginase, Sorafenib, G-CSF, Dexrazoxane, Stem Cell Transplant, Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
Drug · Combination Product · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
29 Days to 21 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Madera, California • Orange, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
Active, not recruiting Phase 3 Interventional

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

NCT03020030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

NCT04283656
View directory record Official record
Conditions
Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
Interventions
Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg, Placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 25, 2026, 10:23 AM EDT
Recruiting Not applicable Interventional

EOIFP Block Versus OSTAP Block for Upper Abdominal Surgery

NCT06409156
View directory record Official record
Conditions
Open Abdominal Surgery
Interventions
Oblique Subcostal Transversus Abdominis Plane Block, External Oblique Intercostal Fascial Plane block
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
Terminated Phase 4 Interventional Results available

ITM vs QL for Pediatric Open Lower Abdominal Procedures

NCT05506930
View directory record Official record
Conditions
Pain Control, Ureteral Reimplantation, Pediatrics, Intrathecal Morphine
Interventions
Intrathecal Morphine, Quadratus lumborum block
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Months to 11 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder

NCT02069366
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases

NCT02416466
View directory record Official record
Conditions
Liver Metastases
Interventions
anti-CEA CAR-T cells, Sir-Spheres
Biological · Device
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

NCT03706469
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 T2, TAK-831 T3
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 25, 2026, 10:23 AM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

NCT03500445
View directory record Official record
Conditions
Myeloma, Multiple Myeloma
Interventions
Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 10:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Native Chicory Inulin on Change and Persistence of Gut Microbiota

NCT06528041
View directory record Official record
Conditions
Healthy
Interventions
Inulin, Maltodextrin
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 25, 2026, 10:23 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

NCT00914628
View directory record Official record
Conditions
Acute Leukemia (Category)
Interventions
HSV-Tk, T-cell depleted or T-cell replete strategies
Genetic · Other
Lead sponsor
AGC Biologics S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

NCT01258751
View directory record Official record
Conditions
Healthy
Interventions
PF-05212377
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Results available

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

NCT03532451
View directory record Official record
Conditions
Bladder Cancer
Interventions
Nivolumab, Nivolumab/Lirilumab
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Tampa, Florida • New York, New York • The Bronx, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 10:23 AM EDT